

# TEST REQUISITION

## Client Information

Account #: .....  
 Account Name: .....  
 Phone: .....  
 Fax: .....  
 Street Address: .....  
 City: .....  
 State: ..... Zip: .....

Check this box if the patient consented to be contacted about potential clinical trials related to the molecular findings.

## Billing Information for Orders by Non-Members

**Required:** Please include face sheet and front/back of patient's insurance card.

Specimen Origin  Hospital Patient (in)  Hospital Patient (out)  
 (Must Choose 1):  Non-Hospital Patient

Bill to:  Client Bill  Insurance  
 Medicare  Patient/Self-Pay  
 Bill charges to other Hospital/Facility:

ICD code (required) .....

## Diagnosis/Patient History

### Solid Tumors

Type  NSCLC  Colorectal Cancer  Melanoma  
 Ovarian  Breast  Brain  Prostate  
 Endometrial  Stomach  Esophageal  
 Other, Specify: .....

Stage  Primary  Metastasis

If Metastasis, list Primary: .....

Relapse  ICD code .....

Other Stage .....

Please include most recent copy of pathology report

### Hematologic Tumors

AML  MDS  MPN  DLBCL  ALL  
 CLL  Lymphoma  Myeloma  
 Other, Specify: .....

Please include most recent copy of pathology report and CBC

Other Relevent Information **Ethnicity:** .....  
**Family History:** .....  
**Other:** .....

## Patient Information

Last Name: .....

First Name: .....

M.I.: ..... Gender:  Male  Female

Date of Birth: (mm/dd/yyyy): .....

Medical Record #: .....

Requisition completed by: .....

Date: (mm/dd/yyyy): .....

Ordering Physician (please print: Last, First): .....

NPI#: .....

Treating Physician (please print: Last, First): .....

The undersigned certifies that he/she is licensed to order the test(s) listed below and that such test(s) are medically necessary for the care/treatment of this patient.

Authorized Signature: .....

Date: (mm/dd/yyyy): .....

## Specimen Information

Collection Date: ..... Time: .....

Specimen ID/ Block ID: .....

10% Neutral Buffered Formalin  Other

Fixative/Preservative: .....

Hospital Discharge Date: .....

Body Site: .....

Peripheral Blood: EDTA-Purple Top(s) ..... Other: .....

Bone Marrow: EDTA-Purple Top(s) ..... Other: .....

Fluid: CSF ..... Pleural ..... Other: .....

FNA cell block: .....

Slides # ..... Unstained: ..... Stained: .....

H&E .....  Paraffin Block(s) #: .....

## Test Selection

### Solid Tumors Tests

Test	Type	Genes
<input type="checkbox"/> <b>GTC-Solid Tumor Profile Plus</b>	DNA & RNA	434/> 1600
<input type="checkbox"/> Add PD-L1 IHC	IHC	
<input type="checkbox"/> Add FOLR1 IHC	IHC	
<input type="checkbox"/> Add CLDN.18	IHC	
<input type="checkbox"/> Include tumor cell of origin		
<input type="checkbox"/> MGMT Methylation (Brain cancer)		

**GTC-Liquid Trace™ Solid Tumor** DNA & RNA 302/> 1600

Blood only

Request tissue for tumor informed testing

CSF

**GTC-Solid Tumor Profile** DNA 434

MGMT Methylation (Brain cancer)

**GTC-Fusion/Expression Profile** RNA > 1600

### Hematologic Tumors Tests

**GTC-Hematology Profile Plus** DNA & RNA 302/> 1600

**GTC-Liquid Trace™ Hematology** DNA & RNA 302/> 1600

CSF

**GTC-Hematology Profile** DNA 302

**Other Test:** .....

## Solid Tumors Tests Comparison Table

Solid Tumor Profile Plus	Liquid Trace® Solid Tumor	Solid Tumor Profile	Solid Tumor Fusion/ Expression Profile
Genes: 434/>1600	Genes: 302/>1600	Genes: 434	Genes: >1600
TAT: 7-10 Days	TAT: 5-7 Days	TAT: 5-7 Days	TAT: 7-10 Days
<b>Indications</b>	<b>Indications</b>	<b>Indications</b>	<b>Indications</b>
All solid tumors Fusions: ALK, ROS1, RET, NTRK1/2/3, and more. BRAF, CIC, EWSR1, PD-L1, MET exon 14 skipping and various alternative splicing, MET, HER2, EGFR, Gene amplifications, PIK3CA, PTEN, AKT1, RAS and HRD Cancer of unknown primary (CUP) T- & B-cell clonality analysis	All solid tumors Chromosomal abnormalities, gene amplifications, HRR, MRD, Fusions: ALK, ROS1, RET, NTRK1/2/3, and more. BRAF, CIC, EWSR1, PD-L1, MET exon 14 skipping and various alternative splicing, MET, HER2, PIK3CA, PTEN, Gene amplifications, AKT1, RAS, HER2, MYC, EGFR, HPV, EBV, TTV, T- & B-cell clonality analysis	All solid tumors: Mutations in 434 genes, copy number variation and chromosomal structural abnormalities, TMB, MSI, HRD	All Solid tumors: Fusion: ALK, ROS1, RET, BRAF, NTRK1/2/3, FGFR1/2/3/4, CIC, EWSR1 & other sarcoma genes Expression: PD-L1, MYC, CCND1, MET, FGFR1/2/3/4, Ki67, ERBB2, MDM2 Alternative splicing: MET exon 14 skipping, EGFRvIII, NTRK, Mutations in more than 1600 genes T- & B-cell clonality analysis
Sample Type: <b>FFPE</b>	Sample Type: <b>Peripheral blood</b>	Sample Type: <b>FFPE</b>	Sample Type: <b>FFPE</b>
Sample Requirements	Sample Requirements	Sample Requirements	Sample Requirements
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative	8-10 mL. EDTA tube is required RNA stability is 48-72 hours from blood draw. DNA stability is 7 days from blood draw. <b>Samples received beyond 72 hours may include only DNA results.</b>	1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative	1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
Results Reported: <b>DNA + RNA</b>	Results Reported: <b>DNA + RNA</b>	Results Reported: <b>DNA</b>	Results Reported: <b>RNA</b>

√ Diagnostic √ Therapeutic √ Prognostic √ Heterogeneity √ Clinical trial matching

## Hematology Tests Comparison Table

Hematology Profile Plus	Liquid Trace® Hematology	Hematology Profile
Genes: 302/>1600	Genes: 302/>1600	Genes: 302
TAT: 7-10 Days	TAT: 5-7 Days	TAT: 5-7 Days
<b>Indications</b>	<b>Indications</b>	<b>Indications</b>
All hematologic neoplasms including lymphoma Classification and diagnosis of lymphoma, multiple myeloma, acute lymphoblastic leukemia, and acute myeloid leukemia Includes IgVH Chromosomal abnormalities, and gene amplifications T- & B-cell clonality analysis	All hematologic neoplasms including lymphoma multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia, MDS, CMML, MPN, MRD, VEXAS syndrome, EBV, HPV, TTV, Chromosomal abnormalities, and gene amplifications, T- & B-cell clonality analysis	All hematologic neoplasms including lymphoma MDS, CMML, AML, MPN (JAK2, CALR, MPL), MRD, multiple myeloma, and other hematologic diseases
Sample Type	Sample Type	Sample Type
Bone marrow, Peripheral blood, Fresh tissue	Peripheral blood	Bone marrow, Peripheral blood, Fresh tissue
Sample Requirements	Sample Requirements	Sample Requirements
Bone marrow: 2ml. Peripheral blood: 5 ml. EDTA tube preferred FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative	8-10 mL. EDTA tube is required RNA stability is 48-72 hours from blood draw. DNA stability is 7 days from blood draw. <b>Samples received beyond 72 hours may include only DNA results.</b>	Bone marrow: 2ml. Peripheral blood: 5 ml. EDTA tube preferred FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
Results Reported: <b>DNA + RNA</b>	Results Reported: <b>DNA + RNA</b>	Results Reported: <b>DNA</b>

√ Diagnostic √ Therapeutic √ Prognostic √ Heterogeneity √ Clinical trial matching

Visit GTC's website to explore the complete gene lists:

[Solid Tumor DNA Genes](#) | [Hematology DNA Genes](#) | [cfDNA Genes](#) | [RNA & cfRNA Genes](#)